Valneva takes again cost of chikungunya vaccine provide in Asia
Valneva and the Serum Institute of India (SII) have ended a license settlement for chikungunya vaccine provide in Asia after solely a 12 months of working collectively.
The settlement, signed in December 2024, noticed Valneva accomplice with SII to assist the supply of the previous firm’s one-shot vaccine, which is understood beneath the model title Ixchiq in permitted areas, in low-and-middle-income international locations (LMICs). SII is the world’s largest producer of vaccines by variety of doses.
Uncover B2B Advertising and marketing That Performs
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Nevertheless, only a 12 months on, the 2 firms have determined to discontinue the settlement. Valneva stated it needed to “assume direct management over its provide chain and commercialisation for endemic high-risk international locations.”
The French vaccine speicalist didn’t instantly reply to Pharmaceutical Know-how when requested for additional remark.
In July 2024, the Coalition for Epidemic Preparedness Improvements (CEPI) gave $41.3m in funding to Valneva to develop entry of Ixchiq. This included supporting medical trials in weak teams, in addition to aiding know-how switch to a further producer to produce the vaccine to Asian LMICs.
Chikungunya, attributable to its namesake virus, is a mosquito-borne illness primarily present in tropical areas. Probably the most affected subcontinental area in Asia is the southeast, with India reporting the very best variety of instances in 2025, as per information from the European Centre for Illness Prevention and Management.
For some time, Ixchiq was the one licensed vaccine in opposition to the virus, although this modified when Bavarian Nordic’s Vimkunya entered the market in February 2025.
Security considerations linked to Ixchiq created a turbulent previous 12 months for Valneva. In August 2025, the US Meals and Drug Administration (FDA) banned Ixchiq amid stories of great antagonistic occasions (SAEs). The licence suspension means the vaccine – a key product in Valneva’s industrial portfolio – is at present prohibited from being shipped or offered within the US. Europe lifted a short lived restriction on the vaccine in July 2025.
In monetary stories from the primary nine-months of 2025, the corporate downgraded its 2025 steerage, regardless of income progress. Valneva stated it anticipated gross sales of between €155m ($179.7m) and €170m, down from a €170m-€180m goal revealed in its Q1 report.
In November, Valneva determined to lower its operational footprint in France by shutting a facility tasked with each operational and analysis and improvement (R&D) actions. In an emailed assertion to Pharmaceutical Know-how on the time, an organization spokesperson stated that 30 positions could be terminated as a part of the transfer.
Ixchiq is certainly one of three industrial vaccines developed by Valneva, alongside Ixiaro/Jespect for Japanese encephalitis and Dukoral for cholera.
Join our each day information round-up!
Give your small business an edge with our main business insights.
